Association of plasma and cortical amyloid beta is modulated by APOE ε4 status

Alzheimer's and Dementia

Volumn 10, Issue 1, 2014, Pages

  Swaminathan, Shanker ^a   Risacher, Shannon L ^a   Yoder, Karmen K ^a   West, John D ^a   Shen, Li ^a   Kim, Sungeun ^a   Inlow, Mark ^a,b   Foroud, Tatiana ^a   Jagust, William J ^c   Koeppe, Robert A ^d   Mathis, Chester A ^e   Shaw, Leslie M ^f   Trojanowski, John Q ^f   Soares, Holly ^g   Aisen, Paul S ^h   Petersen, Ronald C ⁱ   Weiner, Michael W ^j   Saykin, Andrew J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSE HULMAN INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MAYO CLINIC   (United States)

^j SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Alzheimer's disease; Alzheimer's Disease Neuroimaging Initiative; Amyloid beta; Apolipoprotein E; Mild cognitive impairment; Pittsburgh compound B; Plasma amyloid beta; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E EPSILON 4; APOLIPOPROTEIN E4; CARBON 11; PITTSBURGH COMPOUND B; UNCLASSIFIED DRUG;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; FEMALE; GENOTYPE; HUMAN; INFERIOR FRONTAL GYRUS; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ALZHEIMER'S DISEASE; ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE; AMYLOID BETA; APOLIPOPROTEIN E; MILD COGNITIVE IMPAIRMENT; PITTSBURGH COMPOUND B; PLASMA AMYLOID BETA; POSITRON EMISSION TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEINS E; BRAIN; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 84891167140     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.01.007     Document Type: Article

References (48)

1. Alzheimer's Association 2012 Alzheimer's disease facts and figures Alzheimers Dement 8 2012 131 168
2. H. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, and J. Hardy et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat Rev Drug Discov 9 2010 560 574
3. R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, and E. Kokmen Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 1999 303 308 (Pubitemid 29120227)
4. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
5. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects Ann Neurol 65 2009 403 413
6. O.C. Okonkwo, M.M. Mielke, H.R. Griffith, A.R. Moghekar, R.J. O'Brien, and L.M. Shaw et al. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment Arch Neurol 68 2011 113 119
7. P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, and O. Hansson Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
8. G.D. Rabinovici, and W.J. Jagust Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo Behav Neurol 21 2009 117 128
9. S.R. Choi, J.A. Schneider, D.A. Bennett, T.G. Beach, B.J. Bedell, and S.P. Zehntner et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue Alzheimer Dis Assoc Disord 26 2012 8 16
10. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, and M.A. Mintun et al. Use of florbetapir-PET for imaging beta-amyloid pathology JAMA 305 2011 275 283
11. C.R. Jack Jr., V.J. Lowe, M.L. Senjem, S.D. Weigand, B.J. Kemp, and M.M. Shiung et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain 131 2008 665 680 (Pubitemid 351294719)
12. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B Ann Neurol 55 2004 306 319 (Pubitemid 38269583)
13. D.F. Wong, P.B. Rosenberg, Y. Zhou, A. Kumar, V. Raymont, and H.T. Ravert et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18) J Nucl Med 51 2010 913 920
14. R. Mayeux, and N. Schupf Blood-based biomarkers for Alzheimer's disease: plasma Abeta40 and Abeta42, and genetic variants Neurobiol Aging 32 2011 S10 S19
15. F. Song, A. Poljak, M. Valenzuela, R. Mayeux, G.A. Smythe, and P.S. Sachdev Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease J Alzheimers Dis 26 2011 365 375
16. A. Koyama, O.I. Okereke, T. Yang, D. Blacker, D.J. Selkoe, and F. Grodstein Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis Arch Neurol 69 2012 824 831
17. M. Thambisetty, and S. Lovestone Blood-based biomarkers of Alzheimer's disease: challenging but feasible Biomark Med 4 2010 65 79
18. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, and G.W. Small et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 261 1993 921 923 (Pubitemid 23275809)
19. A.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George-Hyslop, M.A. Pericak-Vance, and S.H. Joo et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease Neurology 43 1993 1467 1472 (Pubitemid 23230526)
20. L.A. Farrer, L.A. Cupples, J.L. Haines, B. Hyman, W.A. Kukull, and R. Mayeux et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis: APOE and Alzheimer Disease Meta Analysis Consortium JAMA 278 1997 1349 1356 (Pubitemid 27449696)
21. E.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, and W. Lee et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease Proc Natl Acad Sci U S A 106 2009 6820 6825
22. J.B. Toledo, H. Vanderstichele, M. Figurski, P.S. Aisen, R.C. Petersen, and M.W. Weiner et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI Acta Neuropathol 122 2011 401 413
23. J.E. Donahue, and C.E. Johanson Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease J Neuropathol Exp Neurol 67 2008 261 270 (Pubitemid 351507482)
24. J.M. Castellano, J. Kim, F.R. Stewart, H. Jiang, R.B. DeMattos, and B.W. Patterson et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance Sci Transl Med 3 2011 89ra57
25. M.J. Sharman, M. Morici, E. Hone, T. Berger, K. Taddei, and I.J. Martins et al. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice J Alzheimers Dis 21 2010 403 409
26. K. Nishitsuji, T. Hosono, T. Nakamura, G. Bu, and M. Michikawa Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model J Biol Chem 286 2011 17536 17542
27. A.M. Fagan, M.A. Mintun, R.H. Mach, S.Y. Lee, C.S. Dence, and A.R. Shah et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans Ann Neurol 59 2006 512 519 (Pubitemid 43358072)
28. J.K. Lui, S.M. Laws, Q.X. Li, V.L. Villemagne, D. Ames, and B. Brown et al. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging J Alzheimers Dis 20 2010 1233 1242
29. D.P. Devanand, N. Schupf, Y. Stern, R. Parsey, G.H. Pelton, and P. Mehta et al. Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment Neurology 77 2011 125 131
30. M.W. Weiner, P.S. Aisen, C.R. Jack Jr., W.J. Jagust, J.Q. Trojanowski, and L. Shaw et al. The Alzheimer's Disease Neuroimaging Initiative: progress report and future plans Alzheimers Dement 6 2010 202 211
31. W.J. Jagust, S.M. Landau, L.M. Shaw, J.Q. Trojanowski, R.A. Koeppe, and E.M. Reiman et al. Relationships between biomarkers in aging and dementia Neurology 73 2009 1193 1199
32. W.J. Jagust, D. Bandy, K. Chen, N.L. Foster, S.M. Landau, and C.A. Mathis et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core Alzheimers Dement 6 2010 221 229
33. K.J. Friston, A.P. Holmes, K.J. Worsley, J.P. Poline, C.D. Frith, and R.S.J. Frackowiak Statistical parametric maps in functional imaging: a general linear approach Hum Brain Mapp 2 1994 189 210 (Pubitemid 124008664)
34. S. Swaminathan, L. Shen, S.L. Risacher, K.K. Yoder, J.D. West, and S. Kim et al. Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort Brain Imaging Behav 6 2012 1 15
35. C.R. Jack Jr., M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, and D. Harvey et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods J Magn Reson Imaging 27 2008 685 691 (Pubitemid 351508080)
36. S.L. Risacher, A.J. Saykin, J.D. West, L. Shen, H.A. Firpi, and B.C. McDonald et al. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort Curr Alzheimer Res 6 2009 347 361
37. M.J. Figurski, T. Waligorska, J. Toledo, H. Vanderstichele, M. Korecka, and V.M. Lee et al. Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients Alzheimers Dement 8 2012 250 260
38. A.J. Saykin, L. Shen, T.M. Foroud, S.G. Potkin, S. Swaminathan, and S. Kim et al. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans Alzheimers Dement 6 2010 265 273
39. R Core Team R: a language and environment for statistical computing 2012 R Foundation for Statistical Computing Vienna, Austria
40. J.L. Lancaster, L.H. Rainey, J.L. Summerlin, C.S. Freitas, P.T. Fox, and A.C. Evans et al. Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward-transform method Hum Brain Mapp 5 1997 238 242 (Pubitemid 27375521)
41. J.L. Lancaster, M.G. Woldorff, L.M. Parsons, M. Liotti, C.S. Freitas, and L. Rainey et al. Automated Talairach atlas labels for functional brain mapping Hum Brain Mapp 10 2000 120 131 (Pubitemid 30456920)
42. W.J. Strittmatter, A.M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, and G.S. Salvesen et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease Proc Natl Acad Sci U S A 90 1993 1977 1981 (Pubitemid 23069980)
43. W.J. Strittmatter, K.H. Weisgraber, D.Y. Huang, L.M. Dong, G.S. Salvesen, and M. Pericak-Vance et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease Proc Natl Acad Sci U S A 90 1993 8098 8102 (Pubitemid 23260862)
44. D.E. Schmechel, A.M. Saunders, W.J. Strittmatter, B.J. Crain, C.M. Hulette, and S.H. Joo et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease Proc Natl Acad Sci U S A 90 1993 9649 9653 (Pubitemid 23315843)
45. C. Bachmeier, D. Paris, D. Beaulieu-Abdelahad, B. Mouzon, M. Mullan, and F. Crawford A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier Neurodegener Dis 11 2013 13 21
46. C. Bachmeier, D. Beaulieu-Abdelahad, F. Crawford, M. Mullan, and D. Paris Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier J Mol Neurosci 49 2013 270 276
47. P.B. Jones, K.W. Adams, A. Rozkalne, T.L. Spires-Jones, T.T. Hshieh, and T. Hashimoto et al. Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid-beta in human Alzheimer brain PLoS One 6 2011 e14586
48. N. Bien-Ly, Y. Andrews-Zwilling, Q. Xu, A. Bernardo, C. Wang, and Y. Huang C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-beta (Abeta) and acts in concert with Abeta to elicit neuronal and behavioral deficits in mice Proc Natl Acad Sci U S A 108 2011 4236 4241